STALLERGENES S.A. (Euronext Paris), a global healthcare company specialized in the diagnosis and treatment of allergies through allergen immunotherapy-based solutions, has today announced the opening of its affiliate in Canada.

The aim of this new affiliate, based in Ontario, is to provide innovative treatments to allergy specialists and their patients suffering from allergic respiratory diseases. Stallergenes has recently brought its sublingual grass pollen immunotherapy tablet Oralair®, the immunotherapy gold standard in Europe for treating seasonal allergies, to the Canadian market.

Stallergenes appointed Christina Porter as General Manager of its Canadian affiliate, as of 1 October 2014. A Canadian national, Christina has 15 years' extensive experience in sales and marketing in the pharmaceutical industry, including 9 years at EMD Serono in sales, marketing and management, and as Business Unit Director.

She said: "Establishing our own entity in Canada will enable us to strengthen our relationships with allergy specialists.  We are keen to provide innovative and patient-friendly treatment options for Canadian allergy sufferers."  

In recent years, Stallergenes has expanded substantially at an international level and, having doubled its global presence over the past 3 years, now operates in 21 countries. The Group is expanding outside Europe, notably in Russia, Australia, Argentina, Turkey and the Middle East.

ABOUT RESPIRATORY ALLERGIES IN CANADA

The prevalence of respiratory allergies in Canada is estimated to be similar to that seen in Europe, with approximately 20% to 25% of the adult Canadian population affected, amongst whom 50% are allergic to grass pollen1.  Sublingual therapies such as Oralair® represent a significant step forward for Canadian patients, both in terms of safety and quality of life.  

1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur  Respir J 2004;24:758-64

distributed by